Compare Salesforce Inc (CRM) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs GSK plc — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: Salesforce Inc is far larger — about 2× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and GSK plc for 93 Days on average.
| CRM | GSK | |
|---|---|---|
Market Cap | $187.48B | $91.88B |
Volume | 6,155,822 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $266.23 | $61.18 |
52-Week Low | $150.12 | $43.24 |
Typical Hold Time | 89 Days | 93 Days |
Enterprise Value | $217.82B | $111.88B |
Dividend Yield | 0.77% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% today, but remains under technical pressure with a bearish signal. The company demonstrates strong fundamentals with consistent earnings beats, 77.28% gross margins, and 21.99% net income margins. Recent AI-driven growth initiatives show promise, with Agentforce and Data 360 ARR reaching $2.9 billion. However, the stock faces headwinds from broader software sector weakness and AI disruption concerns.
The investment case balances strong profitability and AI monetization potential against sector-wide pressures. With 76.5% analyst buy ratings and a $271.91 consensus target offering 19% upside, the stock appears fundamentally undervalued. Key risks include AI competition, macroeconomic sensitivity, and the recent 35% YTD decline testing investor patience despite solid financial performance.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
